0913693 B.C. Ltd (REPCF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of 0913693 B.C. Ltd $0.00, price $0.00, upside +0.0%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch 0913693 B.C. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons.
Show more
0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy for aging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also involved in the developing DermaPrecise, a dermal injection device. 0913693 B.C. Ltd. has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize programs. The company was formerly known as RepliCel Life Sciences Inc. and changed its name to 0913693 B.C. Ltd. in March 2025. 0913693 B.C. Ltd. is based in Vancouver, Canada.
Stock analysis
0913693 B.C. Ltd (REPCF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $0.0002 per share, and 2 of the 5 models we run sit above the $0.0001 price.
Bear case: the Earnings-Based group reads lowest at $0.0001, and 3 of the 5 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
0913693 B.C. Ltd reported revenue of C$353K in FY2025 versus C$354K in FY2021, a compound 0.0%/yr. Reported net income was −C$402K in FY2025.
Key figures
Market cap $7.0K · P/S ratio 0.02 · EPS (TTM) $−0.0100 · Net margin −114% · Return on assets (EBIT) −209% · Revenue (TTM) C$354K · EPS growth (YoY) −58.2% · Free cash flow −C$296K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 0%, REPCF screens richer than that median.
Fair Value models
Bear $0.0001Fair Value $0.0001Bull $0.0001
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Start year 2020 (pandemic)
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.5%
’13
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−375.4% (2020) → 67.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks
Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score35 · Below median
Fair Value upside+0.0% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets121.9% · Top 25%
Net margin (TTM)−113.6% · Bottom 25%
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.02× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is 0913693 B.C. Ltd (REPCF) overvalued or undervalued?
As of Sep 29, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of REPCF?
Our model-based fair value for 0913693 B.C. Ltd is $0.0001 (as of Sep 29, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of REPCF?
0913693 B.C. Ltd has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 0913693 B.C. Ltd (REPCF)?
Our model-based price target is the fair value of $0.0001 (as of Sep 29, 2026) from 5 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the 0913693 B.C. Ltd stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of 0913693 B.C. Ltd (REPCF)?
0913693 B.C. Ltd reported trailing-twelve-month revenue of about C$354K (latest available figure, as of Sep 29, 2026).
What is the intrinsic value of 0913693 B.C. Ltd (REPCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 0913693 B.C. Ltd it is $0.0001 per share (as of Sep 29, 2026), against a price of $0.0001. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is 0913693 B.C. Ltd stock overvalued or undervalued in 2026?
As of Sep 29, 2026, REPCF trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of REPCF?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For 0913693 B.C. Ltd the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is 0913693 B.C. Ltd worth?
The market values 0913693 B.C. Ltd at about $7.0K (market capitalisation, as of Sep 29, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of 0913693 B.C. Ltd (REPCF)?
Balance-sheet figures for 0913693 B.C. Ltd (as of Sep 29, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is REPCF from its 52-week high?
0913693 B.C. Ltd trades at $0.0001, at its 52-week high of $0.0001 and at the low of $0.0001 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to 0913693 B.C. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 0913693 B.C. Ltd stock attractive at the current price?
The data as of Sep 29, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 32/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of REPCF calculated?
We run 0913693 B.C. Ltd through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. 0913693 B.C. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 0913693 B.C. Ltd (REPCF)?
The closing price on Sep 25, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 0913693 B.C. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of 0913693 B.C. Ltd
How large is the market capitalisation of 0913693 B.C. Ltd (REPCF)?
The market capitalisation of 0913693 B.C. Ltd is $7.0K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of 0913693 B.C. Ltd (REPCF)?
The price-to-sales ratio of 0913693 B.C. Ltd is 0.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of 0913693 B.C. Ltd (REPCF)?
Earnings per share at 0913693 B.C. Ltd are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of 0913693 B.C. Ltd (REPCF)?
The net margin of 0913693 B.C. Ltd is −114% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of 0913693 B.C. Ltd (REPCF)?
On an EBIT basis the return on assets of 0913693 B.C. Ltd is −209% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast are earnings growing at 0913693 B.C. Ltd (REPCF)?
Earnings per share at 0913693 B.C. Ltd are growing −58.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does 0913693 B.C. Ltd (REPCF) generate?
The free cash flow of 0913693 B.C. Ltd is −C$296K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does 0913693 B.C. Ltd (REPCF) carry?
The net debt of 0913693 B.C. Ltd is C$1.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch 0913693 B.C. Ltd in the live analysis
One click puts 0913693 B.C. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 29, 2026